Your browser doesn't support javascript.
loading
Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center.
Robalino Gonzaga, Ernesto; Farooq, Aimen; Mohammed, Abdul; Chandan, Saurabh; Fawwaz, Baha; Singh, Gurdeep; Malik, Amna; Zhang, Yiyang; Kadkhodayan, Kambiz.
Afiliação
  • Robalino Gonzaga E; Department of Gastroenterology, AdventHealth, Orlando, FL 32804, USA.
  • Farooq A; Department of Gastroenterology, AdventHealth, Orlando, FL 32804, USA.
  • Mohammed A; Department of Gastroenterology, AdventHealth, Orlando, FL 32804, USA.
  • Chandan S; Center for Interventional Endoscopy, AdventHealth, Orlando, FL 32803, USA.
  • Fawwaz B; Department of Gastroenterology, AdventHealth, Orlando, FL 32804, USA.
  • Singh G; Department of Internal Medicine, AdventHealth, Orlando, FL 32804, USA.
  • Malik A; Department of Internal Medicine, AdventHealth, Orlando, FL 32804, USA.
  • Zhang Y; Center for Collaborative Research, AdventHealth Research Institute, Orlando, FL 32804, USA.
  • Kadkhodayan K; Center for Interventional Endoscopy, AdventHealth, Orlando, FL 32803, USA.
J Clin Med ; 13(18)2024 Sep 12.
Article em En | MEDLINE | ID: mdl-39336890
ABSTRACT

Background:

Glucagon-like peptide receptor agonists (GLP-1 RAs) are associated with delayed gastric emptying and may increase the risk of aspiration due to retained gastric contents. There are no guidelines on peri-endoscopic use of GLP-1 RAs, and real-world outcomes in an ambulatory setting remain unknown. This study reports real-world data from an ambulatory center associated with a large tertiary hospital.

Methods:

A retrospective review of electronic medical records was conducted for patients who underwent esophagogastroduodenoscopy (EGD) at a hospital-based outpatient center from January to June 2023. Exclusions included non-elective procedures, current opioid use, altered foregut anatomy, and known gastroparesis. All patients were on GLP-1 RAs before endoscopy and followed standard fasting protocols. Adverse event rates were recorded, and patients were divided into cohorts based on GLP-1 RA use. Univariate and multivariate regression analyses identified risk factors for food retention and complications.

Results:

A total of 1438 patients underwent elective EGD during the study period. Among the 1046 patients included, 73 (7%) were on GLP-1 RAs. The procedure was aborted in four patients (0.4%) due to gastric food retention, with two (50%) on GLP-1 RAs. Independent risk factors for food retention included GLP-1 RA use (OR 9.19; 95% CI 2.73-30.8; p = 0.0003) and diabetes (OR 5.6; 95% CI 1.72-18.2; p = 0.004). Tirzepatide showed the strongest association (p = 0.0056). Factors that did not impact food retention included A1c, BMI, and gender. Protective factors were age (OR 0.96; 95% CI 0.93-0.99; p = 0.02) and same-day colonoscopy (OR 0.18; 95% CI 0.06-0.58; p = 0.003).

Conclusions:

GLP-1 RA use in diabetics increases the risk of retained gastric contents during elective EGD, particularly with tirzepatide, without increasing aspiration risk. Patients undergoing simultaneous colonoscopy had a lower risk of retained gastric contents. Further studies are needed to evaluate the impact of GLP-1 RAs on gastric food retention and procedural risk.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article